PARP1 and Alzheimer disease: The levels of both PARP1 and CD38 were found to be higher in AD as compared to controls, which reduces the NAD+ levels and thereby decreases the SIRT activity (Strosznajder et al., 2012; Fang et al., 2016; Martire et al., 2016).